‘Prime Editing’ Therapy That Directly Corrects Genetic Mutations Begins Clinical Trials in the U.S.
Recently, a new technology capable of treating genetic diseases has been gaining attention. The U.S. Food and Drug Administration (FDA) has recently approved clinical trials for a therapeutic agent utilizing 'Prime Editing' technology, which directly corrects genetic mutations.
The subject of this clinical trial is a rare disease called 'microcystic lymphatic malformation.' Patients have faced significant difficulties as there have been no approved treatments for this condition until now. This therapeutic agent works by directly identifying the faulty part of a gene and correcting it to its normal state.
Prime editing technology is considered more precise than existing gene-editing tools. It has the advantage of reducing side effects because it modifies only the necessary parts accurately without cutting the DNA. The scientific community expects this technology to open new paths for treating intractable diseases.
This clinical trial is providing great hope to patients suffering from the disease. Depending on the results of the upcoming clinical trials, it appears that a new shift will occur in the field of gene therapy. Many experts are looking forward to the successful completion of this research.